For the time being, there is no date for its arrival in the public network and, according to the Brazilian Association of Vaccine Clinics, Qdenga was passed by the National Health Surveillance Agency (ANVISA) past March to provide broad protection against the disease.

For those who had no previous infection Qdenga´s effectiveness was 66.2% and 76.1% for those who had been previously infected.

In practice, the new vaccine developed by the global biopharmaceutical company Takeda Pharma Ltda. is composed of four different serotypes of the virus causing the disease.

Tecnocold Vacunas, a distributor specialized in vaccines, which is part of the Viveo ecosystem, is one of the companies that will be in charge of distributing the new drug.

“We have now a new vaccine. We are part of this trajectory and we want to participate in reduction and control of dengue”, the specialist at Tecnocold Vacunas André Almeida said.

ANVISA specified Qdenga is indicated for children aged over 4, teens and adults up to 60 years of age; unlike previously approved immunizer (Dengvaxia) which can only be applied for those who have already been infected with dengue.

Qdenga is administered subcutaneously in a two-dose schedule, with an interval of three months between applications.

According to Dr. Amanda Alecrim, regional representative of the Brazilian Society of Immunization, dengue is a mosquito-borne viral disease occurring in tropical and subtropical areas.

It is also the most prevalent urban arbovirosis in the Americas, mainly in Brazil, causing a great impact on collective health.

Dr. Alecrim acknowledged “there are no remedies for treating dengue so far. We can only control the vector with sanitary measures, and now we can count on a strong and effective vaccine to be protected from dengue”.

She assured that the powerful Qdenga vaccine will protect all from four dengue serotypes and can be used for those who have had previously infected and also for those who have not yet had contact with the virus.

pll/ocs